Nurse practitioners improve quality of care in chronic kidney disease: Two-year results of a randomised study

Netherlands Journal of Medicine

Volumn 69, Issue 11, 2011, Pages 517-526

  van Zuilen, A D ^a   Blankestijn, P J ^a   van Buren, M ^b   ten Dam, M T G J ^c   Kaasjager, K A H ^d   Ligtenberg, G ^e   Sijpkens, Y W J ^f   Sluiter, H E ^g   van de Ven, P J G ^h   Vervoort, G ⁱ   Vleming, L ^b   Bots, M L ^a   Wetzels, J F M ⁱ  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e Dutch Health Care Insurance Board ^*  (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g DEVENTER HOSPITAL   (Netherlands)

^h Maasstad Hospital Rotterdam   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood pressure; Cardiovascular disease; Chronic kidney disease; Clinical epidemiology; Dyslipidaemia

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SODIUM; VITAMIN D;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NURSE PRACTITIONER; NURSING CARE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PHYSICIAN; PRACTICE GUIDELINE; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; SINGLE BLIND PROCEDURE; SMOKING CESSATION; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NETHERLANDS; NURSE PRACTITIONERS; QUALITY OF HEALTH CARE; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION;

EID: 83755225493     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study. J Am Soc Nephrol. 2007 Oct 1;18(10):2766-72.
2. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med. 1998 Jun 22;158(12):1340-5.
3. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92.
4. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84.
5. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.
6. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New Engl J Med. 2008 Jun 12;358(24):2560-72.
7. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Ann Intern Med. 2003 Aug 19;139(4):244-52.
8. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.
9. Strippoli GFM, Craig JC, Schena FP. The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology. J Am Soc Nephrol. 2004 Feb 1;15(2):411-9.
10. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd B. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001 Mar;37(3):484-9.
11. Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol. 2008 May;21(3):261-7.
12. De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006 Feb;69(3):538-45.
13. Van Zuilen AD, Blankestijn PJ, Van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, et al. Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrol Dial Transplant. 2010 Nov;25(11):3647-54.
14. Van Zuilen AD, Blankestijn PJ, Van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, et al. Hospital specific factors affect quality of blood pressure treatment in chronic kidney disease. Neth J Med. 2011 May 1;69(5):229-36.
15. Mundinger MO, Kane RL, Lenz ER, Totten AM, Tsai WY, Cleary PD, et al. Primary care outcomes in patients treated by nurse practitioners or physicians: a randomized trial. JAMA. 2000 Jan 5;283(1):59-68.
16. Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, et al. Coaching patients On Achieving Cardiovascular Health (COACH): A Multicenter Randomized Trial in Patients With Coronary Heart Disease. Arch Intern Med. 2003 Dec 8;163(22):2775-83.
17. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, et al. A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction. Ann Intern Med. 1994 May 1;120(9):721-9.
18. Schulz KF, Altman DG, Moher D, for the CONSORT Group*. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med. 2010 Mar 24;11:32.
19. Van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, Van Buren M, Ten Dam MA, et al. Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. J Nephrol. 2005 Jan;18(1):30-4.
20. Van Zuilen AD, Van der Tweel I, Blankestijn PJ, Bots ML, Van Buren M, Ten Dam MA, et al. Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials. 2006;7:8.
21. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005 Mar;16(3):763-73.
22. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations in the Estimation of GFR in Health and in Chronic Kidney Disease. J Am Soc Nephrol. 2005 Feb;16(2):459-66.
23. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004 Dec 21;141(12):929-37.
24. Verhave JC, Gansevoort RT, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Drawbacks of the Use of Indirect Estimates of Renal Function to Evaluate the Effect of Risk Factors on Renal Function. J Am Soc Nephrol. 2004 May 1;15(5):1316-22.
25. Tonelli M. Should CKD be a coronary heart disease risk equivalent? Am J Kidney Dis. 2007 Jan;49(1):8-11.
26. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005 Mar;45(3):473-84.
27. Standards of Medical Care in Diabetes - 2006. Diabetes Care. 2006 Jan;29(suppl 1):s4-s42.
28. American Diabetes Association. Standards of Medical Care in Diabetes - 2009. Diabetes Care. 2009 Jan;32(Supplement 1):S13-S61.
29. Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003 Dec;56(12):1163-9.
30. Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000 Sep 9;11:a0828.
31. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet. 2005 Apr 30;365(9470):1591-5.
32. Denver EA, Barnard M, Woolfson RG, Earle KA. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care. 2003 Aug;26(8):2256-60.
33. Woodward A, Wallymahmed M, Wilding J, Gill G. Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabet Med. 2006 Jul;23(7):780-7.
34. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes. Diabetes Care. 2007 Jun;30(6):1374-83.
35. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009 Jan;59(558):43-8.
36. McLachlan A, Kerr A, Lee M, Dalbeth N. Nurse-led cardiovascular disease risk management intervention for patients with gout. Eur J Cardiovasc Nurs. 2010 Jun;2:94-100.
37. Ketola E, Makela M, Klockars M. Individualised multifactorial lifestyle intervention trial for high-risk cardiovascular patients in primary care. Br J Gen Pract. 2001 Apr;51(465):291-4.
38. Ellis G, Rodger J, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing. 2005 Jul;34(4):389-92.
39. Koelewijn-van Loon MS, van der WT, van SB, Ronda G, Winkens B, Severens JL, et al. Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial. CMAJ. 2009 Dec 8;181(12):E267-E274.
40. Goessens BM, Visseren FL, Sol BG, de Man-van Ginkel JM, van der GY. A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular Prevention by Nurses Study (VENUS). Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):996-1003.
41. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes. Diabetes Care 2007 Jun;30(6):1374-83.
42. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300.
43. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. The Lancet. 2005 Oct 8;366(9493):1267-78.
44. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000 Jul 8;356(9224):147-52.
45. Rabelink TJ. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? Nephrol Dial Transplant. 2004 Jan 1;19(1):23-6.
46. Barrett BJ, Garg AX, Goeree R, Levin A, Molzahn A, Rigatto C, et al. A Nurse-coordinated Model of Care versus Usual Care for Stage 3/4 Chronic Kidney Disease in the Community: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2011 Jun;6(6):1241-7.
47. Gaede P, Beck M, Vedel P, Pedersen O. Limited impact of lifestyle education in patients with Type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. Diabet Med. 2001 Feb;18(2):104-8.
48. Bredie SJ, Fouwels AJ, Wollersheim H, Schippers GM. Effectiveness of Nurse Based Motivational Interviewing for smoking cessation in high risk cardiovascular outpatients: A randomized trial. Eur J Cardiovasc Nurs. 2010 Jul 10;174-9.
49. Hollis JF, Lichtenstein E, Vogt TM, Stevens VJ, Biglan A. Nurse-assisted counseling for smokers in primary care. Ann Intern Med. 1993 Apr 1;118(7):521-5.
50. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der MK. Preventing weight gain: one-year results of a randomized lifestyle intervention. Am J Prev Med. 2009 Oct;37(4):270-7.
51. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med. 2001 Jan 4;344(1):3-10.
52. Donnelly JE, Hill JO, Jacobsen DJ, Potteiger J, Sullivan DK, Johnson SL, et al. Effects of a 16-Month Randomized Controlled Exercise Trial on Body Weight and Composition in Young, Overweight Men and Women: The Midwest Exercise Trial. Arch Intern Med. 2003 Jun 9;163(11):1343-50.
53. Hooper L, Smith GD, Ebrahim S. Cochrane reviews on dietary advice for reducing intakes of fat and salt. Eur J Clin Nutr. 2006 Jul;60(7):926-8.
54. Morabia A, Costanza MC. Multiple health behavior change interventions: tell us what you see. Prev Med 2010 Jan;50(1-2):1-2.
55. Werch CE, Moore MJ, Bian H, Diclemente CC, Huang IC, Ames SC, et al. Are effects from a brief multiple behavior intervention for college students sustained over time? Prev Med. 2010 Jan;50(1-2):30-4.
56. Blokstra A, van Dis I, Verschuren WMM. Efficacy of multifactorial lifestyle interventions in patients with established cardiovascular diseases and high risk groups. Eur J Cardiovasc Nurs. [Epub ahead of print]
57. Lisspers J, Sundin Í, Íhman A, Hofman-Bang C, Rydqn L, Nygren. Long-Term Effects of Lifestyle Behavior Change in Coronary Artery Disease: Effects on Recurrent Coronary Events After Percutaneous Coronary Intervention. Health Psychology. 2005 Jan;24(1):41-8.
58. Jacobs N, De Bourdeaudhuij I, Thijs H, Dendale P, Claes N. Effect of a cardiovascular prevention program on health behavior and BMI in highly educated adults: A randomized controlled trial. Patient Educ Couns. 2010 Sep 30.
59. Ter Wee PM, Jorna AT. [Treatment of patients with chronic renal insufficiency; a guideline for internists]. Ned Tijdschr Geneeskd. 2004 Apr 10;148(15):719-24.
60. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004 May 1;43(5 Suppl 1):S1-290.
61. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl 2009 Aug;(113):S1-130.
62. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Jr., Rovin BH. Renoprotection: one or many therapies? Kidney Int. 2001 Apr;59(4):1211-26.